| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
85,210,000 |
| Market
Cap: |
93.73(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.01 - $5.55 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Allakos is a clinical stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. Co.'s antibodies are lirentelimab (AK002) and AK006. Co. is developing lirentelimab for the treatment of eosinophilic gastritis/eosinophilic duodenitis, eosinophilic esophagitis, atopic dermatitis, chronic spontaneous urticaria and potentially additional indications. AK006 targets Siglec-6, an inhibitory receptor selectively expressed on various cells. AK006 appears to have the potential to provide various cell inhibition than lirentelimab.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
4,459,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$22,384,180 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  More Robert J |
member - potential 10% group |
– – – |
2021-03-05 |
4 |
S |
$115.83 |
$1,493,040 |
D/D |
(12,676) |
0 |
|
36% |
|
| Nohra Guy P |
10% Owner |
– – • |
2021-03-04 |
4 |
S |
$108.89 |
$2,876,742 |
D/D |
(25,768) |
0 |
|
32% |
|
| More Robert J |
member - potential 10% group |
– – – |
2021-03-04 |
4 |
S |
$108.36 |
$1,673,184 |
D/D |
(15,000) |
12,676 |
|
32% |
|
| More Robert J |
member - potential 10% group |
– – – |
2021-03-03 |
4 |
S |
$110.89 |
$552,094 |
D/D |
(4,878) |
27,676 |
|
30% |
|
| Rasmussen Henrik S Md |
Chief Medical Officer |
• – – |
2021-03-03 |
4 |
OE |
$1.16 |
$23,250 |
D/D |
20,000 |
123,771 |
|
- |
|
| Rasmussen Henrik S Md |
Chief Medical Officer |
• – – |
2021-03-03 |
4 |
AS |
$112.83 |
$2,480,244 |
D/D |
(21,952) |
103,771 |
|
-30% |
|
| Tomasi Adam |
President, COO and CFO |
• – – |
2021-03-03 |
4 |
AS |
$113.56 |
$362,143 |
D/D |
(3,189) |
153,126 |
|
-30% |
|
| Asbury Mark |
CLOGC and Secretary |
• – – |
2021-03-02 |
4 |
D |
$117.82 |
$86,362 |
D/D |
(733) |
63,242 |
|
- |
|
| Rasmussen Henrik S Md |
Chief Medical Officer |
• – – |
2021-03-02 |
4 |
OE |
$1.16 |
$23,250 |
D/D |
20,000 |
125,087 |
|
- |
|
| Rasmussen Henrik S Md |
Chief Medical Officer |
• – – |
2021-03-02 |
4 |
AS |
$117.32 |
$2,346,400 |
D/D |
(20,000) |
105,087 |
|
-28% |
|
| Rasmussen Henrik S Md |
Chief Medical Officer |
• – – |
2021-03-02 |
4 |
D |
$117.82 |
$155,051 |
D/D |
(1,316) |
103,771 |
|
- |
|
| Alexander Robert |
Chief Executive Officer |
• • – |
2021-03-02 |
4 |
D |
$117.82 |
$458,320 |
D/D |
(3,890) |
245,395 |
|
- |
|
| Tomasi Adam |
President, COO and CFO |
• – – |
2021-03-02 |
4 |
A |
$117.82 |
$202,297 |
D/D |
1,717 |
156,315 |
|
- |
|
| Rasmussen Henrik S Md |
Chief Medical Officer |
• – – |
2021-03-01 |
4 |
OE |
$1.16 |
$23,250 |
D/D |
20,000 |
125,087 |
|
- |
|
| Rasmussen Henrik S Md |
Chief Medical Officer |
• – – |
2021-03-01 |
4 |
AS |
$120.66 |
$2,413,200 |
D/D |
(20,000) |
105,087 |
|
-29% |
|
| Mckearn John P |
Director |
– • – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
I/I |
8,016 |
8,639 |
|
- |
|
| Mckearn John P |
Director |
– • – |
2021-02-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(47,494) |
4,887,932 |
|
- |
|
| 3x5 Rivervest Fund Ii-B, L.p. |
10% Owner |
– – • |
2021-01-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(862,574) |
4,887,932 |
|
- |
|
| Mckearn John P |
Director |
– • • |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
I/I |
623 |
623 |
|
- |
|
| Mckearn John P |
Director |
– • • |
2021-01-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(862,574) |
4,935,426 |
|
- |
|
| Alta Partners Nextgen Fund I, L.p. |
10% Owner |
– – • |
2021-01-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,441,735) |
0 |
|
- |
|
| Alta Partners Nextgen Fund I, L.p. |
10% Owner |
– – • |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
I/I |
441,735 |
339,084 |
|
- |
|
| Alexander Robert |
Chief Executive Officer |
• • – |
2020-12-29 |
4 |
OE |
$4.31 |
$35,535 |
D/D |
8,240 |
241,105 |
|
- |
|
| Tomasi Adam |
President, COO and CFO |
• – – |
2020-12-29 |
4 |
OE |
$4.31 |
$23,357 |
D/D |
5,416 |
157,757 |
|
- |
|
| Holles Natalie C. |
Director |
– • – |
2020-12-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,600 |
|
-24% |
|
135 Records found
|
|
Page 5 of 6 |
|
|
0.03 (2.65%) 
